Company intelligence / Profile preview
Novassay
Epalinges / Lausanne region / Yverdon-les-Bains*, Switzerlandnovassay.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
Novassay is developing a pipeline of ion channel-targeting therapeutics for neuropathic pain and oncology. Its lead small molecule candidate NVA1309 is at the GLP/toxicology stage with unique properties such as non-brain penetration and high potency over pregabalin. The company also has monoclonal antibody programs targeting α2δ subunits for both neurological diseases and cancer. No clinical results have been reported yet[3][7].
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small moleculeMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical partnerships publicly disclosed as of June 2025. The company expresses interest in R&D collaborations[1].
Beyond the preview
Go deeper on Novassay.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novassay.